Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report?
by Zacks Equity Research
Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod
by Zacks Equity Research
BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
by Zacks Equity Research
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
Options Traders Expect Huge Moves in Endo International (ENDP) Stock
by Zacks Equity Research
Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.
BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y
by Zacks Equity Research
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
Kohl???s, Endo International and Costco as Zacks Bull and Bear of the Day
by Zacks Equity Research
Kohl???s, Endo International and Costco as Zacks Bull and Bear of the Day
Bear of the Day: Endo International (ENDP)
by Madeleine Johnson
Litigation has hit this opioid drug maker hard. Is there any chance for a rebound?
What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
by Zacks Equity Research
BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.
Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.
New Strong Sell Stocks for February 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?
by Zacks Equity Research
Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.
Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse
by Zacks Equity Research
Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
by Zacks Equity Research
Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.
Implied Volatility Surging for Endo (ENDP) Stock Options
by Zacks Equity Research
Endo (ENDP) needs investors to pay close attention to the stock based on moves in the options market lately.
Should Value Investors Consider Endo International (ENDP) Stock?
by Zacks Equity Research
Lets put Endo International plc (ENDP) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Will Endo (ENDP) Continue to Disappoint Investors in 2017?
by Zacks Equity Research
Endo (ENDP) a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, is under significant pressure due to intensifying consortium pricing pressures and additional competitive entrants and product discontinuations.
BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
by Zacks Equity Research
BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.
Endo International (ENDP) Jumps: Stock Rises 6.9%
by Zacks Equity Research
Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.
BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.
Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.